HUTCHMED (China) Limited (HKG:0013)
21.20
+0.40 (1.92%)
May 16, 2025, 4:08 PM HKT
HUTCHMED (China) Revenue
In the year 2024, HUTCHMED (China) had annual revenue of $630.20M USD, down -24.80%. HUTCHMED (China) had revenue of $324.52M in the half year ending December 31, 2024, with 44.64% growth.
Revenue
$630.20M
Revenue Growth
-24.80%
P/S Ratio
3.71
Revenue / Employee
$347.99K
Employees
1,811
Market Cap
18.16B HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 630.20M | -207.80M | -24.80% |
Dec 31, 2023 | 838.00M | 411.59M | 96.52% |
Dec 31, 2022 | 426.41M | 70.28M | 19.73% |
Dec 31, 2021 | 356.13M | 128.15M | 56.21% |
Dec 31, 2020 | 227.98M | 23.09M | 11.27% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeiGene | 32.53B |
Hansoh Pharmaceutical Group Company | 13.05B |
JD Health International | 61.89B |
WuXi Biologics | 19.87B |
Alibaba Health Information Technology | 31.39B |
Innovent Biologics | 10.03B |
Akeso | 2.26B |
Sino Biopharmaceutical | 30.72B |
HUTCHMED (China) News
- 24 days ago - HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025 - GlobeNewsWire
- 25 days ago - AIM Market Roundup: Catenai, Seeen, Hutchmed - The Armchair Trader
- 26 days ago - HUTCHMED Completes Enrollment for Phase II Trial of Savolitinib in Gastric Cancer | HCM stock news - GuruFocus
- 26 days ago - HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China - GlobeNewsWire
- 4 weeks ago - Hutchmed weighs cancer drug’s supply-chain options amid US-China trade war - South China Morning Post
- 2 months ago - HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma - GlobeNewsWire
- 2 months ago - Intended Retirement of Independent Non-executive Directors and changes of composition of board committees - GlobeNewsWire
- 2 months ago - US pharma restrictions won't affect Hutchmed operations, says CEO - CNBC